{"contentid": 488669, "importid": NaN, "name": "Gamma Biosciences takes controlling stake in Mirus Bio", "introduction": "California, USA-based Gamma Biosciences has as agreed to make a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, Wisconsin.", "content": "<p>California, USA-based Gamma Biosciences has as agreed to make a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, Wisconsin. Current Mirus shareholders will retain a substantial equity ownership stake in the company.</p>\n<p>The transaction will support Mirus&rsquo; plans to expand good manufacturing practice (GMP) production and commercialization of its flagship product <em>Trans</em>IT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further development and commercialization of the platform for in vivo delivery applications</p>\n<p>Originally developed for therapeutic delivery of RNA, Mirus LPNCs have been adapted for a wide range of gene delivery applications. Demand for efficient and scalable gene delivery technologies continues to increase as larger volumes of viral vector are required to support the growing number of gene therapies in development. <em><a href=\"https://www.mirusbio.com/products#tags:dna%20transfection\">TransIT&reg; VirusGen and Mirus&rsquo; portfolio of additional products and services</a></em>&nbsp;enable customers at both research and clinical scales achieve cost effective, industry leading functional titers.</p>\n<p>Mirus will leverage Gamma Bio&rsquo;s strategic and commercial resources and will work closely with its other operating companies to deliver an increasingly comprehensive range of solutions for the advanced therapy industry.</p>\n<p>&ldquo;Highly efficient, GMP compliant nucleic acid delivery into a wide variety of cell types will continue to be a critical path item for advanced therapies, from viral vectors such as AAV for gene therapy to engineered cellular therapies to novel mRNA based vaccines,&rdquo; said Matt Gunnison, president of Gamma Biosciences, adding: &ldquo;Mirus brings decades of experience in transfection and cell engineering and a portfolio of best-in-class transfection products for in vitro and in vivo delivery, adding a new foundational platform that complements Gamma&rsquo;s existing offering in advanced therapy manufacturing.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-05-19 10:34:00", "meta_title": NaN, "meta_keywords": "Gamma Biosciences, Mirus Bio, Equity stake, Controlling, Investment, Viral vectors, Gene therapy", "meta_description": "Gamma Biosciences takes controlling stake in Mirus Bio", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-19 10:32:35", "updated": "2021-05-19 10:38:59", "access": NaN, "url": "https://www.thepharmaletter.com/article/gamma-biosciences-takes-controlling-stake-in-mirus-bio", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merger-large.jpg", "image2id": "merger-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy", "topic_tag": "Companies, mergers and acquisitions", "geography_tag": "USA", "company_tag": "Gamma Biosciences, Mirus Bio", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-19 10:34:00"}